Vaccinex (VCNX) Revenue & Revenue Breakdown
Vaccinex Revenue Highlights
Latest Revenue (Y)
$570.00K
Latest Revenue (Q)
$232.00K
Main Segment (Y)
Exclusive Product License
Main Geography (Y)
Exclusive Product License
Vaccinex Revenue by Period
Vaccinex Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $570.00K | 470.00% |
| 2022-12-31 | $100.00K | -88.89% |
| 2021-12-31 | $900.00K | 1700.00% |
| 2020-12-31 | $50.00K | -90.44% |
| 2019-12-31 | $523.00K | -27.76% |
| 2018-12-31 | $724.00K | 704.44% |
| 2017-12-31 | $90.00K | -71.52% |
| 2016-12-31 | $316.00K | - |
Vaccinex generated $570.00K in revenue during NA 2023, up 470.00% compared to the previous quarter, and up 78.73% compared to the same period a year ago.
Vaccinex Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $232.00K | 123.08% |
| 2024-03-31 | $104.00K | -126.94% |
| 2023-12-31 | $-386.00K | -2030.00% |
| 2023-09-30 | $20.00K | 100.00% |
| 2023-06-30 | - | -100.00% |
| 2023-03-31 | $550.00K | 1000.00% |
| 2022-12-31 | $50.00K | - |
| 2022-09-30 | $50.00K | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | -100.00% |
| 2021-12-31 | $850.00K | 1600.00% |
| 2021-09-30 | $50.00K | 100.00% |
| 2021-06-30 | - | -100.00% |
| 2021-03-31 | $850.00K | 1600.00% |
| 2020-12-31 | $50.00K | - |
| 2020-09-30 | $50.00K | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | -100.00% |
| 2019-09-30 | $404.00K | 1516.00% |
| 2019-06-30 | $25.00K | -73.40% |
| 2019-03-31 | $94.00K | -51.55% |
| 2018-12-31 | $194.00K | -2.02% |
| 2018-09-30 | $198.00K | 57.14% |
| 2018-06-30 | $126.00K | -38.83% |
| 2018-03-31 | $206.00K | 128.89% |
| 2017-12-31 | $90.00K | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | - |
Vaccinex generated $232.00K in revenue during Q2 2024, up 123.08% compared to the previous quarter, and up 42.18% compared to the same period a year ago.
Vaccinex Revenue Breakdown
Vaccinex Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 21 | Dec 19 |
|---|---|---|---|
| Exclusive Product License | $500.00K | $850.00K | - |
| Exclusive Research Tool License | - | - | $100.00K |
| Exclusive Product License Option | - | - | $300.00K |
Vaccinex's latest annual revenue breakdown by segment (product or service), as of Dec 23: Exclusive Product License (100.00%).
Quarterly Revenue by Product
| Product/Service | Sep 22 | Sep 21 | Mar 21 | Sep 19 |
|---|---|---|---|---|
| Exclusive Product License | $50.00K | $50.00K | $850.00K | $100.00K |
| License | - | - | $850.00K | - |
| Exercise Of Product Option | - | - | - | $300.00K |
Vaccinex's latest quarterly revenue breakdown by segment (product or service), as of Sep 22: Exclusive Product License (100.00%).
Vaccinex Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 21 | Dec 19 |
|---|---|---|
| Exclusive Product License | $850.00K | - |
| Exclusive Product License Option | - | $300.00K |
| Exclusive Research Tool License | - | $100.00K |
Vaccinex's latest annual revenue breakdown by geography, as of Dec 21: Exclusive Product License (100.00%).
Quarterly Revenue by Country
| Country | Sep 22 | Sep 21 | Mar 21 | Sep 19 |
|---|---|---|---|---|
| Exclusive Product License | $50.00K | $50.00K | $850.00K | $100.00K |
| License | - | - | $850.00K | - |
| Exercise Of Product Option | - | - | - | $300.00K |
Vaccinex's latest quarterly revenue breakdown by geography, as of Sep 22: Exclusive Product License (100.00%).
Vaccinex Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| SABS | SAB Biotherapeutics | $2.24M | $263.14K |
| VCNX | Vaccinex | $570.00K | $232.00K |
| ANEB | Anebulo Pharmaceuticals | - | - |
| FBRX | Forte Biosciences | - | - |
| TARA | Protara Therapeutics | - | - |
| ERAS | Erasca | - | - |
| FWBI | Entero Therapeutics | - | - |
| RNXT | RenovoRx | - | - |
| GOVX | GeoVax Labs | - | - |
| MNPR | Monopar Therapeutics | - | - |
| SRZN | Surrozen | - | - |
| ELDN | Eledon Pharmaceuticals | - | - |
| SLRX | Salarius Pharmaceuticals | - | - |
VCNX Revenue FAQ
What is Vaccinex’s yearly revenue?
Vaccinex's yearly revenue for 2023 was $570K, representing an increase of 470.00% compared to 2022. The company's yearly revenue for 2022 was $100K, representing a decrease of -88.89% compared to 2021. VCNX's yearly revenue for 2021 was $900K, representing an increase of 1700.00% compared to 2020.
What is Vaccinex’s quarterly revenue?
Vaccinex's quarterly revenue for Q2 2024 was $232K, a 123.08% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $104K, a -126.94% decrease from the previous quarter (Q4 2023), and a -81.09% decrease year-over-year (Q1 2023). VCNX's quarterly revenue for Q4 2023 was $-386K, a -2030.00% decrease from the previous quarter (Q3 2023), and a -872.00% decrease year-over-year (Q4 2022).
What is Vaccinex’s revenue growth rate?
Vaccinex's revenue growth rate for the last 3 years (2021-2023) was -36.67%, and for the last 5 years (2019-2023) was 8.99%.
What are Vaccinex’s revenue streams?
Vaccinex's revenue streams in c 23 are Exclusive Product License
What is Vaccinex’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Vaccinex was Exclusive Product License. This segment made a revenue of $500K, representing 100.00% of the company's total revenue.